Between September 2023 and May 2025, the Federal Trade Commission challenged more than 600 patent listings in the FDA’s Orange Book. Courts affirmed the first major delisting orders. Teva paid $35 million to settle a class-action antitrust case tied directly to improper listings. And in December 2025, Teva removed more than 200 patents from the registry covering more than 30 branded products. The mechanism that brand manufacturers relied on for decades to trigger 30-month stays and push back generic entry is now a liability source, and every NDA holder with device patents, combination product patents, or late-listed secondary patents needs to reassess its portfolio.
This article explains what the Orange Book is, how the 30-month stay works, why device patents became the flashpoint, what the Teva v. Amneal Federal Circuit ruling means for listing standards across all therapeutic areas, and how generic manufacturers, brand companies, investors, and payers should calibrate their strategies in the post-crackdown environment. It also maps the cases still in motion and identifies the product categories most exposed to accelerated loss of exclusivity.
What Is the FDA Orange Book, and Why Does It Control Generic Entry?
The FDA Orange Book is the agency’s official publication listing every drug product approved for safety and effectiveness under Section 505 of the Federal Food, Drug, and Cosmetic Act, along with all associated patent information and regulatory exclusivity periods. Any generic manufacturer filing an Abbreviated New Drug Application (ANDA) must address each listed patent through one of four certifications, and a Paragraph IV certification challenging patent validity or non-infringement triggers automatic 30-month stay of FDA approval if the brand files suit within 45 days.
The full title of the publication is ‘Approved Drug Products with Therapeutic Equivalence Evaluations,’ though everyone in the industry calls it by its color. The Orange Book has been the central traffic-control mechanism for generic pharmaceutical entry since Congress passed the Drug Price Competition and Patent Term Restoration Act of 1984, known universally as Hatch-Waxman.
Before Hatch-Waxman, getting a generic approved required a full new drug application, including clinical trials. That created a barrier most generic manufacturers could not clear economically. The law’s solution was to let generics rely on the brand’s safety and efficacy data as long as they could prove bioequivalence. In exchange, brand manufacturers received patent restoration for time lost during FDA review and the ability to list their patents in the Orange Book so generic challengers had to confront them before receiving final approval.
The result was a structured adversarial system: brand companies list patents, generic companies certify either that they do not infringe or that the patents are invalid, litigation follows, and the first generic filer that wins earns 180 days of market exclusivity. The system worked reasonably well for simple small-molecule drugs with a single active ingredient and one or two clearly relevant patents. It did not anticipate the rise of combination drug-device products like pressurized metered-dose inhalers, auto-injectors, or nasal delivery systems, where the device itself became the platform for secondary patent listings that have little to do with the molecule that actually treats the patient.
How the 30-Month Stay Creates the Financial Incentive for Orange Book Abuse
The 30-month stay is the mechanism that turns an Orange Book listing into real commercial value. When a brand manufacturer receives notice that a generic has filed a Paragraph IV certification, the brand has 45 days to file a patent infringement lawsuit. If it does, the FDA cannot grant final approval to the ANDA for 30 months, or until a court rules in favor of the generic, whichever comes first. The stay requires no judicial review of patent merit. No judge evaluates whether the listed patent is valid or relevant to the approved drug. The listing itself, combined with a filed lawsuit, creates the delay automatically.
This asymmetry matters. A brand company with a patent of dubious relevance to the active ingredient can list it, receive notice of a Paragraph IV challenge, sue immediately, and secure 30 months of blocked generic approval without any court ever ruling that the patent is legitimate. The generic manufacturer bears the legal and financial cost of challenging the stay, and the cost of challenging can make the math unattractive, particularly for lower-revenue drugs or for would-be filers whose first-mover 180-day exclusivity window might not offset years of litigation expense.
DrugPatentWatch tracks Orange Book listings, patent expirations, ANDA filings, and Paragraph IV certifications in real time, giving generic manufacturers and branded companies a comprehensive view of the competitive timeline for any reference listed drug. Their analysis of listing patterns shows that between 2005 and 2015, Orange Book patent listings per drug increased by 53 percent, driven primarily by secondary formulation, device, and method-of-use patents filed after the original NDA approval. [1] That trend is what the FTC set out to reverse.
What Types of Patents Can Be Listed in the Orange Book?
Under 21 U.S.C. § 355(b)(1)(A)(viii), as amended by the FDCA Omnibus reform in 2021, an NDA holder must submit information for any patent that claims the drug for which the application was submitted and approved, and for which a claim of patent infringement could reasonably be asserted against an unauthorized person. The statute specifies two qualifying categories: drug substance (active ingredient) patents and drug product (formulation or composition) patents. Method-of-use patents are also listable if they cover an approved therapeutic indication.
What is not listable under the statute are patents that claim manufacturing processes, packaging, drug delivery devices when those devices do not incorporate the active ingredient in their claims, and patents on distribution systems or risk management programs. The 2021 reform tightened the statutory language and clarified that device patents covering delivery mechanisms without reciting the active pharmaceutical ingredient do not qualify. That amendment gave the FTC and courts a firmer statutory hook when challenging inhaler device patents, auto-injector mechanism patents, and similar listings that had proliferated over the prior decade.
The FTC Orange Book Campaign: From Policy Statement to Patent Avalanche
The FTC’s current enforcement posture did not emerge overnight. The agency published an extensive 2002 study on generic drug entry prior to patent expiration that identified early signs of Orange Book gaming. That study’s conclusions were partially undermined by the 2003 Medicare Modernization Act reforms, which eliminated the ability of brand manufacturers to stack multiple 30-month stays by listing additional patents after initial ANDA filings. But the underlying problem persisted: the FDA, which processes patent listing submissions, does not have the authority or resources to evaluate whether listed patents actually qualify under the statute. It accepts submissions and lists them. The NDA holder certifies under penalty of perjury that listings comply, but there is no pre-listing substantive review.
September 2023: The Policy Statement That Changed the Landscape
On September 14, 2023, the FTC issued a Policy Statement declaring that improper Orange Book patent listings may constitute an unfair method of competition in violation of Section 5 of the FTC Act. This was the first formal agency statement treating listing practice as a potential antitrust violation, not merely a regulatory compliance issue.
The Policy Statement was specific about what the FTC found objectionable: brand manufacturers listing device patents, distribution method patents, and other patents that claim neither the approved drug nor a method of using it. The FTC argued that such listings ‘abuse the regulatory processes set up by Congress to promote generic drug competition,’ resulting in higher costs and reduced access. [2]
Critically, the Statement acknowledged its limits. It was not a binding rule. It did not preclude FDA from continuing its current listing practices. It put market participants on notice that enforcement action was possible, but did not commit to a litigation timeline or specific targets. Several brand manufacturers ignored it entirely.
November 2023: The First Wave of Warning Letters
On November 7, 2023, the FTC followed through with action. It sent warning letters to ten brand pharmaceutical manufacturers and notified the FDA that it was formally disputing more than 100 Orange Book patent listings. The targets included inhaler products, epinephrine autoinjectors (including Kaleo’s AUVI-Q), Restasis multi-dose bottles from AbbVie, and several device-heavy combination products. [3]
The mechanism for an FTC-initiated listing challenge is established in FDA regulations at 21 C.F.R. § 314.53(f)(1). When the FTC files a dispute, the FDA notifies the NDA holder, which has 30 days to either withdraw or amend the listing, or certify under penalty of perjury that the listing complies with applicable statutory and regulatory requirements. Certification means the company is explicitly attesting that the patent is properly listed, which escalates the legal exposure if a court later determines otherwise.
Some manufacturers moved quickly. GlaxoSmithKline and Glaxo Group voluntarily delisted patents on Advair HFA, Flovent HFA, Incruse Ellipta, Breo Ellipta, Anoro Ellipta, Trelegy Ellipta, Arnuity Ellipta, and Ventolin HFA. Kaleo delisted patents on AUVI-Q and its naloxone hydrochloride products. AstraZeneca, Boehringer Ingelheim, and GSK announced commitments to cap inhaler out-of-pocket costs at $35. [4] Teva, meanwhile, declined to delist the patents at issue on its ProAir HFA inhaler, setting up the litigation that would define the legal standard for all subsequent cases.
April 2024: The Second Wave Reaches 300-Plus Listings
The FTC’s April 30, 2024 action dwarfed the first round. The agency sent warning letters to ten brand manufacturers and notified the FDA of disputes involving more than 300 patent listings across 20 different brand-name products. [5] The new targets included Novo Nordisk’s Ozempic (semaglutide injection), GLP-1 receptor agonist injectables and auto-injectors, Amphastar Pharmaceuticals’ Baqsimi glucagon nasal spray, and additional inhaler products from Boehringer Ingelheim, Covis Pharma, Novartis, and Mylan Specialty (a Viatris subsidiary).
The Ozempic listing drew the most media attention. Including a weight-loss blockbuster with annual global revenues exceeding $14 billion in an Orange Book listing dispute sent a clear signal that the FTC was not limiting its campaign to niche inhalers. The device patents at issue covered auto-injector pen components and delivery mechanisms rather than the semaglutide molecule itself, which has its own robust portfolio of composition and formulation patents. The FTC’s position was that listing device patents on injection pens alongside the molecule patents generates 30-month stay exposure for generic applicants even when the challenged patents have nothing to do with the drug’s therapeutic action.
May 2025: The Third Round and the Trump Administration Continuation
Despite a change in administration, the FTC’s Orange Book enforcement campaign continued without interruption. In May 2025, the agency issued another round of warning letters disputing more than 200 additional patent listings, sending letters to Novartis, Amphastar Pharmaceuticals, Mylan Specialty, Covis Pharma, and multiple Teva entities. [6] FTC Chairman Andrew Ferguson framed the action explicitly in terms of the Trump administration’s executive order on lowering drug prices, stating that ‘the American people voted for transparent, competitive, and fair healthcare markets.’ The campaign had become bipartisan policy, which removed any reasonable expectation among brand manufacturers that a new administration would soften enforcement.
Teva v. Amneal: The Federal Circuit Decision That Set the Legal Standard
Background: ProAir HFA and the Device Patent Strategy
Teva’s ProAir HFA is an albuterol sulfate metered-dose inhaler approved under NDA No. 021457. The active ingredient is albuterol sulfate, a short-acting beta-2 agonist used for bronchospasm relief in asthma and COPD. Teva listed five patents in the Orange Book for ProAir HFA, each covering components of the inhaler’s delivery mechanism: specifically, dose counter technology and canister components. None of the five patents included albuterol sulfate in their claims. The active ingredient was not mentioned anywhere in the patent claims. [7]
When Amneal Pharmaceuticals filed ANDA No. 211600 seeking approval for a generic ProAir HFA and submitted Paragraph IV certifications on those five patents, Teva filed suit. The filing triggered the 30-month stay automatically, blocking FDA approval of Amneal’s generic application until at least February 2026 absent litigation resolution. Amneal counterclaimed, alleging the five patents were improperly listed and asserting five antitrust counterclaims including illegal monopolization and attempted monopolization.
What Did the District Court Decide in June 2024?
Judge Stanley Chesler of the U.S. District Court for the District of New Jersey ruled on June 10, 2024. He granted Amneal’s motion for judgment on the pleadings on the delisting counterclaims, holding that Teva’s Inhaler Patents ‘contain no claim for the active ingredient at issue, albuterol sulfate’ and instead ‘are directed to components of a metered inhaler device.’ Under the Listing Statute, 21 U.S.C. § 355(b)(1)(A)(viii), a patent must ‘claim the drug for which the applicant submitted the application.’ The drug in Teva’s NDA was albuterol sulfate HFA inhalation aerosol. The inhaler device components did not claim that drug. [8]
Teva’s primary argument was that a patent ‘claims a product’ if it reads on, meaning is infringed by, any part of the NDA product. The court rejected this entirely. The statutory phrase ‘claim the drug’ requires the patent to specifically claim the therapeutic agent in the product, not merely the housing that contains it. The judge also allowed Amneal’s five antitrust counterclaims to proceed, a significant move that signaled private antitrust litigation over improper listings had a viable path forward even without FTC enforcement action.
Federal Circuit Affirmance: December 20, 2024
On December 20, 2024, the U.S. Court of Appeals for the Federal Circuit affirmed the district court’s delisting order in Teva Branded Pharm. Prods. R&D, Inc. v. Amneal Pharms. of N.Y., LLC, No. 24-1936. The court held that to list a patent in the Orange Book, it must claim the drug from the applicant’s submitted and approved application, which requires the patent to claim at least the active pharmaceutical ingredient.
The Federal Circuit’s opinion went further than the district court in one important respect. It addressed device patents categorically, holding that ‘patents claiming just the device components of the product approved in an NDA do not meet the listing requirement of claiming the drug for which the applicant submitted the application.’ [9] That sentence covers every inhaler mechanism patent, every auto-injector component patent, every nasal spray device patent currently listed in the Orange Book for any drug product. The court also denied Teva’s request that the case be remanded for claim construction, reasoning that even under Teva’s own proposed claim interpretation, the patents did not claim albuterol sulfate.
The Federal Circuit rejected en banc rehearing on March 3, 2025. AstraZeneca and Sanofi-Aventis had filed amicus briefs supporting Teva’s rehearing request, arguing the decision would disrupt the established process for resolving patent disputes and would harm both brand and generic industries. The full court was not persuaded. [10]
What This Means: The New Listing Standard Across All Drug-Device Combinations
The Teva v. Amneal ruling creates a clear, testable standard for every NDA holder with combination drug-device products. To list a patent in the Orange Book, that patent must claim the active pharmaceutical ingredient either directly in the patent claims or through a formulation or composition claim that necessarily incorporates the API. A patent covering only device components, delivery mechanisms, dose counters, cannulas, needle shields, or distribution system features without reciting the active ingredient anywhere in its claims is not listable.
This standard applies immediately to the most commercially significant drug-device combination categories on the market:
Pre-filled syringes and cartridge systems (Victoza, various insulin analogues)
Nasal spray systems (Baqsimi glucagon, Narcan nasal spray)
Any NDA holder who has listed device mechanism patents for these products and has not yet voluntarily delisted them faces litigation exposure and FTC enforcement risk that is now substantially higher than it was before the Federal Circuit’s December 2024 ruling.
The Teva QVAR Settlement: Orange Book Improper Listing as Antitrust Liability
What Was the QVAR Lawsuit About?
The QVAR antitrust case, captioned In re QVAR End-Payor Antitrust Litigation, No. 23-cv-11131 (D. Mass.), was brought by a class of consumers and third-party payors who alleged that Teva improperly listed patents for its QVAR beclomethasone dipropionate HFA inhaler and pursued sham litigation to block cheaper generic versions from entering the market. The settlement class covers consumers and payors in 42 states and the District of Columbia who purchased or reimbursed QVAR products between January 2015 and July 2025. [11]
The $35 Million Settlement and Its Industry Implications
In October 2025, Teva agreed to pay $35 million and to withdraw six QVAR-related patents from the Orange Book to resolve the class action. The settlement marked the first major monetary resolution of a private antitrust claim based on over-inclusive Orange Book filings, according to the law firm Haug Partners. [12] The $35 million represents approximately 11 percent of estimated damages, which means the total alleged harm from QVAR-specific listings alone was calculated by plaintiffs at roughly $320 million.
‘The tension between regulatory compliance and antitrust exposure in Orange Book patent listings reached a dramatic inflection point this fall. Since late 2023, the FTC and private litigants have reframed over-inclusive listings as an anti-competitive tactic, and courts have begun to agree.’Haug Partners LLP, ‘Listing a Liability: The Orange Book’s New Antitrust Frontier’ (November 2025) [12]
The financial calculus for brand manufacturers changed with the QVAR settlement. Before October 2025, improper Orange Book listings carried theoretical antitrust exposure and FTC investigation risk, but no company had actually paid significant money to resolve a private class-action case predicated on the listings themselves. Teva’s $35 million payment confirmed that the private bar can successfully monetize Orange Book enforcement and that end-payor antitrust cases of this type survive to settlement. That precedent creates a roadmap for similar cases against other manufacturers whose challenged listings remain in the Orange Book.
Who Else Is Exposed to Private Antitrust Claims Over Orange Book Listings?
Based on the FTC’s public challenge letters and the products involved, several categories of manufacturers face elevated private litigation exposure. The FTC has publicly challenged listings by:
Novo Nordisk (Ozempic and Saxenda device listings)
AbbVie (Restasis multi-dose)
Companies whose listings were publicly challenged, who certified to the FDA that those listings were proper, and who maintained them in the Orange Book after the Federal Circuit’s ruling in Teva v. Amneal are now in the most precarious position. Their certification that listings comply with the statute becomes increasingly difficult to defend when the Federal Circuit has stated the opposite as a matter of law.
Orange Book Patent Challenge Timeline: 2023 to 2026
September 14, 2023 FTC issues Policy Statement on improper Orange Book listings, putting brand manufacturers on notice that listings claiming devices without active ingredients may violate Section 5 of the FTC Act.
November 7, 2023 FTC sends warning letters to 10 manufacturers challenging 100-plus listings. GlaxoSmithKline, Glaxo Group, and Kaleo delist patents voluntarily. Most other targets certify listings as proper. FTC files amicus brief in Mylan v. Sanofi-Aventis.
March 22, 2024 FTC files amicus brief in Teva v. Amneal at the District Court for the District of New Jersey, arguing that device patents not claiming the active ingredient must be delisted.
April 30, 2024 FTC issues second round of challenges targeting 300-plus listings across 20 brand products. Ozempic device listings challenged for the first time. Warning letters sent to Novo Nordisk, Teva, Boehringer Ingelheim, Covis Pharma, and others.
June 10, 2024 Judge Chesler orders Teva to delist five ProAir HFA inhaler patents from the Orange Book, holding they do not claim albuterol sulfate. Antitrust counterclaims by Amneal allowed to proceed. First federal district court order compelling delisting in an antitrust context.
December 20, 2024 Federal Circuit affirms district court order in Teva v. Amneal, No. 24-1936. Sets binding appellate standard: Orange Book listings must claim at least the active pharmaceutical ingredient. Device-component-only patents are categorically ineligible for listing.
January 22, 2025 Federal Circuit stays the delisting order pending Teva’s en banc rehearing petition.
March 3, 2025 Federal Circuit denies Teva’s en banc rehearing request. Stay lifted. Delisting order takes effect.
May 2025 FTC issues third round of warning letters challenging 200-plus listings at Novartis, Amphastar, Mylan Specialty, Covis Pharma, and Teva entities. FTC Chairman Andrew Ferguson characterizes action as part of Trump administration drug-pricing executive order.
October 2025 Teva agrees to $35 million settlement in In re QVAR End-Payor Antitrust Litigation, the first monetary resolution of a private antitrust case predicated on improper Orange Book listings. Teva to delist six QVAR patents.
December 10, 2025 Under sustained FTC pressure, Teva requests FDA to delist more than 200 patents covering more than 30 asthma, diabetes, COPD, and epinephrine autoinjector products.
April–May 2026 QVAR settlement receives preliminary court approval. FTC and DOJ listening sessions on anticompetitive pharmaceutical practices continue. Multiple ANDA applications previously held up by 30-month stays linked to now-delisted patents advance toward final FDA approval.
Which Products Face the Earliest Generic Entry After Delisting?
Amneal’s ANDA for a generic ProAir HFA was effectively delayed for more than two years by Teva’s device patent listings. With those patents now ordered delisted and the Federal Circuit stay lifted, Amneal’s product is the most immediately positioned for competitive entry in the short-acting beta-agonist inhaler market. The albuterol sulfate molecule itself has been off-patent for many years. The primary remaining barrier was always the device patent strategy. Removing it does not guarantee instant generic availability because Amneal still needs final FDA approval and must clear manufacturing inspections, but the regulatory pathway is now unobstructed. The commercial impact on Teva’s ProAir franchise is direct.
Teva’s $35 million QVAR settlement and the withdrawal of six Orange Book patents for that product create a clear lane for generic beclomethasone HFA inhalers. The molecule has been off-patent for years. The inhaled corticosteroid market for QVAR is relatively modest compared to Advair or Symbicort, but the precedent matters more than the revenue. Plaintiffs’ firms now have a confirmed settlement template for any product where device patents delayed generic entry and where payors can document overcharge damages from the period of delayed competition.
GLP-1 Injectable Products: The Next Frontier
The FTC’s April 2024 challenge to Ozempic device listings was the most commercially significant action in the campaign, not because Ozempic faces imminent generic entry (semaglutide is protected by formulation and method-of-use patents that will not expire until the early 2030s) but because it signaled that the FTC views auto-injector pen mechanism patents as ineligible for Orange Book listing regardless of the product’s revenue profile. Novo Nordisk’s Ozempic, Victoza (liraglutide), and Saxenda (liraglutide, higher dose) all use prefilled pen delivery systems with proprietary device features that the company has listed in the Orange Book alongside the molecule patents.
Delisting the device patents does not change Ozempic’s competitive timeline today, but it changes the risk calculus for any would-be ANDA filer for the molecule. When semaglutide molecule patents begin to expire, the absence of device patent listings means generic and biosimilar manufacturers will not face 30-month stays triggered by injection pen mechanism patents. That matters for planning entry timelines in 2031 to 2034. Investment teams and pipeline planners should note the difference between molecule exclusivity and device exclusivity as a separate, now largely eliminated, layer of the protection stack.
Inhaler Market LOE Acceleration: Which Respiratory Brands Are at Risk?
Product
Active Ingredient
Brand Holder
Device Patents Challenged?
Voluntary Delistings
Earliest Generic Risk
ProAir HFA
Albuterol sulfate
Teva
Yes, court-ordered
Yes (200+ patents, Dec. 2025)
Near-term
QVAR
Beclomethasone dipropionate HFA
Teva
Yes, settled
Yes (6 patents)
Near-term
Advair HFA / Diskus
Fluticasone/salmeterol
GSK
Yes (Nov. 2023)
Yes (voluntary)
Generics already launched
Flovent HFA
Fluticasone propionate
GSK
Yes (Nov. 2023)
Yes (voluntary)
Post-debranding
Breo Ellipta
Fluticasone furoate/vilanterol
GSK
Yes (Nov. 2023)
Yes (voluntary)
Molecule patents remain
Trelegy Ellipta
Fluticasone furoate/umeclidinium/vilanterol
GSK
Yes (Nov. 2023)
Yes (voluntary)
Medium-term
Ventolin HFA
Albuterol sulfate
GSK
Yes (Nov. 2023)
Yes (voluntary)
Generics available
Spiriva / Spiriva Respimat
Tiotropium bromide
Boehringer Ingelheim
Yes
Partial
Molecule patent exposure
Baqsimi
Glucagon
Amphastar / Eli Lilly
Yes (Apr. 2024)
Pending
Dependent on molecule patents
Ozempic
Semaglutide
Novo Nordisk
Device listings challenged
Status unclear
Molecule patents through ~2031
How Does the FTC Orange Book Dispute Process Work in Practice?
Step-by-Step: From Warning Letter to Delisting or Certification
The FDA’s Orange Book dispute mechanism under 21 C.F.R. § 314.53(f)(1) is straightforward in its procedural steps but carries high stakes at each stage. When the FTC files a listing dispute, the following sequence applies:
FTC notifies the FDA in writing that it disputes the accuracy or relevance of a specific patent listing for a specific NDA.
FDA forwards the dispute to the NDA holder and notifies them of the challenge.
The NDA holder has 30 days to either: (a) amend or withdraw the listing, or (b) certify under penalty of perjury that the listing complies with applicable statutory and regulatory requirements.
If the NDA holder certifies, FDA takes no further action on the dispute. The patent remains listed.
If the NDA holder withdraws or amends, FDA removes or modifies the listing in the next Orange Book update.
The dispute record itself is confidential at the FDA level, though the FTC publishes summaries of its challenge actions in press releases.
This process has a structural weakness: there is no mechanism for the FDA to evaluate the merits of the dispute and order delisting absent NDA holder consent. If the brand manufacturer certifies that the patent is properly listed, the FDA has no authority under current regulations to override that certification. Actual delisting against a manufacturer’s will requires either a court order in litigation (as in Teva v. Amneal) or the manufacturer’s voluntary decision to delist after a court ruling or settlement. The FTC, absent a court order, cannot compel delisting through the administrative process alone.
Why Certification Under Penalty of Perjury Is Not a Sufficient Deterrent
The statutory certification requirement exists to create accountability for inaccurate listings. But perjury prosecutions for incorrect patent certifications are essentially nonexistent in the pharmaceutical context. Companies that certify listings as compliant while courts and the FTC take the opposite view have not faced criminal prosecution. The real deterrent is civil antitrust exposure, which the QVAR settlement quantified at $35 million for a single product over a ten-year period, and the reputational cost of defending an indefensible position through years of litigation.
For companies with large portfolios of challenged listings, the aggregate financial exposure is substantial. A product generating $500 million in annual revenues with 5 years of delayed generic entry attributable to improper device patent listings could generate antitrust damages calculated at treble the overcharge, multiplied across payors, states, and insurers. The QVAR settlement at 11 percent of estimated damages suggests that plaintiffs and defendants can reach commercially workable resolutions, but the plaintiffs’ bar now has the template to pursue substantially larger cases against higher-revenue products.
Paragraph IV Certification Strategy After the Delisting Wave
How Generic Manufacturers Should Update Their Certification Analysis
Generic manufacturers filing ANDAs for combination drug-device products should now distinguish between two categories of Orange Book listings: patents that claim the active ingredient in the approved drug (and must be addressed through Paragraph certifications) and patents that claim only device components (which should no longer be listed at all under Teva v. Amneal and should be challenged if they remain).
For listings that survive the new standard, the Paragraph IV strategy calculus has not fundamentally changed. First-filer 180-day exclusivity remains the primary financial incentive for generic entry. What has changed is the quality of the barrier. Before the FTC campaign, a generic filer challenging a device patent in a Paragraph IV certification would trigger a 30-month stay and have to litigate the patent’s validity or non-infringement. Now, generic manufacturers can counterclaim for delisting based on the Federal Circuit standard, obtain a court order compelling removal, and potentially monetize the antitrust harm caused by the improper stay. Amneal’s antitrust counterclaims in Teva v. Amneal are still proceeding at the district court level and could produce a judgment that further increases the cost of improper listings for brand manufacturers.
The ‘Patent Thicket’ Problem: What Remains After Device Patent Delisting
Removing device patents from the Orange Book does not remove the broader problem of patent thickets around high-revenue branded drugs. A patent thicket is the accumulation of multiple secondary patents, including formulation variants, method-of-use patents, polymorph patents, enantiomer patents, and extended-release composition patents, that collectively extend protection well beyond the primary compound patent’s expiration. The DrugPatentWatch database documents that between 2005 and 2015 the number of Orange Book-listed patents per drug increased 53 percent. [1] Device patent elimination addresses one segment of that growth, not the whole pattern.
Method-of-use patents remain the most complicated category. A method patent covering a specific FDA-approved therapeutic indication is listable if it is tied to that approved use. Generic manufacturers can respond with a Section viii statement rather than a Paragraph IV certification, carving out the patented use from their labeling and proceeding without triggering a 30-month stay. This ‘skinny label’ strategy works when the generic can offer the drug for unpatented indications and still capture substantial commercial value. It does not work when the patented indication covers the primary commercial use, or when subsequent judicial interpretation of the use code expands what conduct constitutes infringement.
Paragraph IV vs. Section VIII: Choosing the Right Certification for the Post-Crackdown Era
Jazz Pharmaceuticals v. Avadel: Distribution Method Patents and the Orange Book
Can a REMS Patent Block Generic Entry?
Parallel to the device patent litigation, the Jazz Pharmaceuticals v. Avadel case addressed a different category of improper listing: patents covering distribution risk management systems rather than the drug itself. Jazz Pharmaceuticals listed a patent covering its Risk Evaluation and Mitigation Strategy (REMS) distribution system for Xywav (calcium, magnesium, potassium, and sodium oxybates oral solution) in the Orange Book. Avadel filed an NDA for its own oxybate product, Lumryz, which is a once-nightly formulation of sodium oxybate intended to compete with Jazz’s twice-nightly products. Jazz sued, and the listing triggered a 30-month stay.
The FTC filed an amicus brief arguing that Jazz’s REMS patent was improperly listed. A REMS is a distribution risk management program required by the FDA for certain high-risk drugs; it is a regulatory compliance mechanism, not the drug or a method of treating patients with the drug. Allowing a REMS patent to block ANDA or NDA approval would mean any company that developed a safety distribution system could list that system’s patent to block all competitors from the market indefinitely. The district court and eventually both parties dismissed the case, with Lumryz receiving approval and launching. [13] But the litigation confirmed that the FTC will file amicus briefs in distribution-method and REMS patent cases, and courts are receptive to the agency’s statutory analysis.
Mylan v. Sanofi: Insulin Injector Pen Mechanism Patents
The Mylan v. Sanofi-Aventis case in the Western District of Pennsylvania addressed a related category: whether patents covering the drive mechanism of an insulin injector pen could be listed in the Orange Book for the insulin analogue products those pens deliver. Sanofi had listed patents for two injectable insulin forms, and Mylan’s generic developer arm alleged those listings were improper. The FTC filed a November 2023 amicus brief supporting Mylan’s position without taking a stance on the specific patents at issue. [14]
The First Circuit had already addressed a nearly identical question in a case involving Sanofi’s insulin pen drive mechanism patent, holding that ‘an integral part of an injector pen becomes [neither] the pen itself [nor] in turn a drug’ under the listing statute. That First Circuit precedent, combined with the FTC’s consistent amicus position and the Federal Circuit’s ruling in Teva v. Amneal, creates multi-circuit appellate pressure against device mechanism listing practices throughout the insulin and injectable biologics sectors.
FTC Enforcement Authority Over Orange Book Listings: What Are the Legal Limits?
Does the FTC Have Statutory Power to Compel Delisting?
The FTC does not have direct statutory authority to compel Orange Book patent delistings through an administrative order. The agency’s enforcement tools are Section 5 of the FTC Act (which prohibits unfair methods of competition), civil investigative demands (which compel document production), and civil enforcement actions in federal court. Delisting itself requires either voluntary NDA holder action, a court order in litigation, or FDA administrative correction.
This limitation explains why the FTC’s campaign has relied on a combination of warning letters, FDA dispute filings, amicus briefs in private litigation, civil investigative demands (which Teva received in 2024 for internal communications related to its listing decisions), and public shaming through press releases. The agency’s primary leverage is the threat of a full Section 5 enforcement action, which would be litigated in federal court and could result in both an order requiring delisting and civil penalties. The FTC had not brought a standalone Section 5 Orange Book enforcement action through mid-2026, preferring to support private litigation and use the CID process to incentivize voluntary delisting.
The Washington Legal Foundation raised the question of whether the FTC’s approach was an appropriate exercise of agency power given that the FDA already has a formal dispute mechanism and private parties already have litigation tools. [5] The Federal Circuit’s December 2024 ruling largely resolved that debate in the FTC’s favor: the agency’s analysis of what the listing statute requires was correct, and courts were willing to order delisting on that basis. Whether the FTC will eventually bring a standalone Section 5 case against a manufacturer that refuses to delist after a court ruling is the open question heading into 2026.
What Happens If a Brand Manufacturer Ignores FTC Warning Letters?
Teva’s experience provides the clearest answer. The company received FTC warning letters in November 2023 and April 2024, certified its ProAir HFA device patents as properly listed, received a civil investigative demand requesting internal communications, lost at the district court level, lost on appeal at the Federal Circuit, lost the en banc rehearing petition, and ultimately removed more than 200 patents in December 2025 following continued FTC pressure. The total cost included legal fees for multi-year litigation, a $35 million settlement on a related product, reputational damage as the FTC repeatedly cited Teva by name in its press releases, and the commercial impact of losing the device patent shield across a broad product portfolio.
That outcome will inform other manufacturers’ cost-benefit analysis when they receive FTC challenges to their listings. The legal defense is expensive, the odds are now against the brand following Teva v. Amneal, and the end state for a refused voluntary delistings is typically the same as a compelled one, but with substantial additional costs along the way.
How to Audit Your Orange Book Patent Portfolio Right Now
The Four-Question Compliance Test for NDA Holders
Every NDA holder with combination drug-device products should apply the following analysis to each listed patent before the next ANDA filing triggers a Paragraph IV challenge and potentially activates antitrust exposure:
Does the patent claim the active pharmaceutical ingredient? Read the independent claims of every listed patent. If no independent claim recites the name or structure of the approved active ingredient anywhere in the claim language, the patent cannot be listed under Teva v. Amneal regardless of whether it covers the device used to deliver that ingredient.
Is the patent a drug substance, drug product, or method-of-use patent? These are the three listable categories. A patent that falls into none of these categories, for example a manufacturing process patent, a packaging patent, a distribution system patent, or a dosing device patent without API recitation, should not be in the Orange Book.
Has the FDA or FTC disputed this listing? Check the FTC’s public challenge letters and press releases. DrugPatentWatch maintains updated tracking of challenged Orange Book listings that can expedite this search. If the FTC has challenged a listing and the NDA holder certified it as proper, the litigation and antitrust risk are already elevated.
What is the cost-benefit of maintaining vs. delisting? For any listing that fails tests 1 or 2 above, the remaining question is commercial. Delisting removes a potential 30-month stay trigger but also removes an ability to delay generic entry through the administrative process. In most cases after Teva v. Amneal, the litigation risk of maintaining an improper listing exceeds the commercial value of the potential stay, particularly for lower-revenue products or products facing near-term LOE from molecule patent expiration anyway.
What Patent Counsel and Regulatory Affairs Teams Need to Do Differently
The coordination model for Orange Book compliance needs to change. Historically, patent counsel identified patents that ‘covered’ an approved drug product and submitted them for listing, with regulatory affairs executing the form submission. The legal analysis focused on whether a patent could be asserted in an infringement suit against a generic, not whether it met the specific statutory criteria for Orange Book listing. Those two standards are different: a patent can be infringed by an ANDA product without meeting the Listing Statute’s requirement that it ‘claim the drug.’
Post-Teva v. Amneal, the listing analysis requires patent counsel to evaluate whether each independent claim in each listed patent specifically incorporates the API. Regulatory affairs needs to understand that the duty to certify listings under penalty of perjury now carries real civil liability risk given the antitrust litigation model the QVAR case established. Antitrust counsel should be involved in reviewing any decision to certify and maintain a challenged listing, and should model the potential damages exposure from a future end-payor class action before the brand team concludes that maintaining the listing is commercially worthwhile.
Mayer Brown summarized the new compliance standard clearly: collaboration between patent counsel and FDA regulatory counsel has ‘always been essential,’ but ‘the increasing role of the FTC and private antitrust litigation means that antitrust counsel review should also be considered.’ [3]
Patent Thickets, Evergreening, and the Broader Market Context
Why Orange Book Gaming Matters Beyond Individual Products
The FTC’s Orange Book campaign fits within a broader policy agenda on pharmaceutical competition that includes pay-for-delay settlement scrutiny (in the Supreme Court’s 2013 FTC v. Actavis ruling, the Court held reverse payment settlements can violate antitrust laws), biosimilar entry barriers, and the pharmacy benefit manager reform debate. The Orange Book component specifically targets the mechanism by which brand pharmaceutical companies convert regulatory procedures into market exclusivity extensions.
The scale of the problem is measurable. According to a 2021 JAMA Internal Medicine study, the number of Orange Book-listed patents per drug increased 53 percent between 2005 and 2015. [1] A significant portion of that increase came from secondary patents: device mechanism patents, modified delivery system patents, and extended formulation patents that were filed and listed after the primary molecule patent had already granted. The commercial logic was explicit: each additional listing is a potential trigger for a 30-month stay if a generic challenger files a Paragraph IV certification, and the incremental cost of listing an additional patent is essentially zero.
What Is ‘Patent Evergreening’ and How Does Orange Book Listing Enable It?
Patent evergreening is the practice of filing successive secondary patents on minor variations or delivery system improvements for a drug product to extend market exclusivity beyond the original compound patent’s expiration. When those secondary patents are listed in the Orange Book, they generate 30-month stay rights that can delay generic entry even if the secondary patents are ultimately found invalid or non-infringing.
Inhaler products became a primary evergreening battleground because the device engineering is separable from the chemistry. The active ingredients in most asthma inhalers, albuterol, fluticasone, salmeterol, tiotropium, formoterol, budesonide, are all off-patent or approaching expiration. The commercial value of these products was increasingly maintained through proprietary device patents covering inhaler mechanisms, dose counters, actuation systems, and breath-actuated designs. The FTC’s view, now confirmed by the Federal Circuit, is that those device improvements are commercially protectable but not Orange-Book-listable unless they claim the API as part of their protection scope.
This ruling does not prevent brand manufacturers from holding device patents. It prevents them from using device patents to generate 30-month FDA approval stays for generic drug applications. A brand manufacturer can still sue a generic for infringing its dose counter patent, and if the generic’s inhaler truly uses the same mechanism, it can win. But that infringement suit does not trigger a 30-month stay because the patent is not in the Orange Book. The generic receives FDA approval, launches, and the patent dispute is litigated on its own schedule.
Biosimilar Entry and Orange Book Equivalent Mechanisms
Biologic drugs and their biosimilar competitors operate under a different framework from the Orange Book system. The Biologics Price Competition and Innovation Act of 2009 (BPCIA) created a separate pathway for biosimilar applications under 42 U.S.C. § 262. The BPCIA has its own patent dance mechanism, under which the reference product sponsor and biosimilar applicant exchange patent lists and engage in a staged dispute process culminating in possible patent litigation. There is no Orange Book equivalent for biologics, and the 30-month automatic stay does not apply in the same way.
However, the legal principles being developed in Orange Book litigation are relevant to how courts will analyze exclusivity conduct in the biosimilar context. If a biologic manufacturer listens to the FTC’s analysis and the Federal Circuit’s statutory interpretation carefully, a defensive IP strategy built primarily on device or delivery system patents, with minimal reliance on molecule-level protection, is now the riskiest approach to maintaining market exclusivity across both small-molecule and biologic products.
What the Delisting Wave Means for Generic Manufacturers’ Commercial Strategy
First-Mover Recalibration: 180-Day Exclusivity in a Post-Listing Era
Generic manufacturers that filed Paragraph IV certifications against now-delisted device patents face a complex question about their first-filer 180-day exclusivity status. If the challenged patents are removed from the Orange Book before a final judgment on patent validity or non-infringement, the certification becomes moot. Under FDA regulations, a first filer can lose 180-day exclusivity if it fails to market within a certain period after final approval or if a court enters a final judgment of invalidity or non-infringement for all patents it challenged. Delisting itself is neither; the regulatory treatment of exclusivity for certifications against voluntarily or court-ordered delisted patents is an area where FDA guidance is incomplete and company-specific scenarios vary.
The safest course for any first filer whose challenged patents are now delisted is to accelerate its manufacturing readiness, ensure its ANDA is in final approval status, and launch at the first available opportunity. Waiting for administrative clarity on exclusivity while a competing generic manufacturer files its own ANDA and potentially qualifies for its own exclusivity window is the wrong risk profile given the current regulatory environment.
Authorized Generics: How Brand Manufacturers Use Them to Blunt 180-Day Exclusivity
Brand manufacturers facing generic entry after patent delisting or patent loss have an additional defensive tool: the authorized generic. An authorized generic is a version of the brand drug marketed by the NDA holder itself (or through a licensing arrangement) during the first filer’s 180-day exclusivity window. Because the authorized generic is sold under the brand’s NDA rather than the generic’s ANDA, it does not count as a competing generic for exclusivity purposes. The brand can launch its own ‘generic’ at a discount, splitting the volume advantage the first generic filer expected to capture alone during the exclusivity window. This practice reduces the financial incentive for Paragraph IV challenges, which in turn reduces the pressure on brand manufacturers to rationalize their patent listings proactively.
ANDA Backlog and FDA Approval Timelines Post-Delisting
Removing a patent from the Orange Book does not instantly produce a generic competitor. An ANDA must first be filed, reviewed by FDA, cleared of patent and exclusivity obstacles, inspected for manufacturing compliance, and receive tentative or final approval. FDA ANDA review timelines average 12 to 18 months under current performance targets for standard applications, though applications in the queue before a patent delisting may be close to final approval if they were waiting only for the 30-month stay to clear.
Amneal’s ANDA for ProAir HFA is the clearest example: the application was ready for FDA approval as early as April 2024 according to FTC’s amicus brief, but the 30-month stay triggered by Teva’s inhaler device patent litigation blocked it. With those patents now court-ordered delisted and Teva having voluntarily removed 200-plus additional listings, Amneal’s path to final approval is cleared of the stay-generated obstacle. The actual launch date depends on Amneal’s manufacturing readiness and any remaining FDA review activities, not on patent status.
Financial Impact Analysis: LOE Risk for Brand Manufacturers
How Much Revenue Is Directly Exposed to Accelerated Loss of Exclusivity?
The FTC’s own public documentation of the revenue scope of challenged products provides a starting point. GlaxoSmithKline’s voluntarily delisted products, Anoro Ellipta, Trelegy Ellipta, Arnuity Ellipta, and Ventolin HFA, generated combined North American revenues of approximately $2.5 billion in 2023. [5] The Advair HFA, Flovent HFA, Incruse Ellipta, and Breo Ellipta products contributed an additional $1.2 billion in 2023 North American revenue for Glaxo Group before device patent delistings.
For Teva, the revenue exposed through its broader December 2025 delistings covering more than 30 products is harder to quantify because Teva does not break out individual product revenues for many of its branded portfolio items. The ProAir HFA franchise, which is Teva’s primary branded respiratory product in the U.S. market, has generated approximately $300 million to $400 million annually in recent years. The QVAR settlement’s 11 percent-of-estimated-damages calculation implies plaintiffs assessed total overcharge damages at roughly $320 million for that product alone over a ten-year period.
Investor Implications: How Sell-Side Models Should Adjust for Orange Book Risk
Equity research analysts covering branded pharmaceutical companies with significant combination drug-device portfolios need to recalibrate three areas of their models:
First, patent life analysis. For any product with a combination of molecule patents and device patents, remove the device patents from the patent protection stack if those patents do not claim the API and have been or are likely to be challenged. The effective exclusivity period is the molecule patent or regulatory exclusivity expiration, whichever is later, not the most distant patent in the Orange Book listing. DrugPatentWatch’s patent expiration tracking, filtered by patent claim type and listing challenge status, is the most efficient tool for performing this analysis across a large portfolio.
Second, litigation contingency. Any brand manufacturer whose Orange Book listings were challenged by the FTC, who certified those listings as proper after the Federal Circuit’s December 2024 ruling, and who has not since delisted them carries elevated antitrust settlement exposure. Probabilistic loss contingency should be modeled, particularly for products where end-payor class certification is plausible and where damages periods extend back 10 years or more.
Third, pipeline valuation. For combination drug-device products still in Phase III development, the IP strategy needs validation that the device patents planned for Orange Book listing actually claim the API under the new legal standard. Phase III data packages marketed to investors in 2025 and 2026 that include device patent Orange Book listings as a component of the exclusivity story should be re-examined.
Settlement Economics: What Is an Improper Orange Book Listing Worth to Plaintiffs?
Case
Product
Settlement Amount
Estimated Total Damages
Settlement % of Damages
Additional Relief
In re QVAR End-Payor Antitrust Litigation
QVAR (beclomethasone HFA)
$35 million
~$320 million (implied)
~11%
Withdrawal of 6 Orange Book patents
Teva v. Amneal (ProAir HFA)
ProAir HFA (albuterol sulfate)
N/A (ongoing antitrust counterclaims)
TBD
N/A
Court-ordered delisting of 5 inhaler patents
FTC v. AbbVie: The Reverse Payment Settlement Precedent and Its Connection to Orange Book Enforcement
How Pay-for-Delay Settlements Interact With Improper Listings
The FTC’s long-running campaign against reverse payment settlements in Hatch-Waxman litigation established that brand manufacturers cannot pay generic challengers to stay out of the market when the payments are more than the avoided litigation cost. FTC v. AbbVie, Inc. (3d Cir. 2020) found that AbbVie had used sham litigation based on Orange Book patents to coerce generic rivals into accepting anticompetitive settlements for Androgel. [15] The court’s analysis connected the quality of the patent to the legitimacy of the litigation: if the patent was used as a litigation tool rather than a genuine IP enforcement mechanism, the resulting settlement was more likely to cross into antitrust violation territory.
The same logic applies to device patents. If a brand manufacturer lists a device patent in the Orange Book knowing it does not claim the API (which the Federal Circuit has now confirmed is the statutory standard), and then uses that listing to trigger a 30-month stay that it leverages into a settlement or consent decree, the entire sequence has antitrust exposure. The chain from improper listing to stay to anticompetitive settlement is cleaner and more provable now than it was before Teva v. Amneal gave plaintiffs a definitive statement of the legal standard the brand violated.
Competitive Intelligence: Companies Whose Listings Still Face Challenge
Novartis: Remaining Orange Book Exposure
Novartis received FTC warning letters in both April 2024 and May 2025 regarding inhaler product listings. The company’s Onbrez Breezhaler and Seebri Breezhaler, along with combination products, have been the primary targets. Unlike GSK, which moved quickly to delist voluntarily in November 2023, Novartis has maintained contested listings while the legal environment clarified. Following the Federal Circuit’s December 2024 ruling and the en banc denial in March 2025, Novartis’s continued listing of any device patents that fail the API-claim test carries the same antitrust exposure profile that Teva demonstrated with ProAir HFA and QVAR.
Boehringer Ingelheim: Spiriva and Stiolto Listings
Boehringer Ingelheim’s respiratory portfolio generates substantial global revenue. Spiriva HandiHaler and Spiriva Respimat, tiotropium bromide inhaler products, have been among the most commercially durable branded inhalers. The Respimat soft mist inhaler is itself a platform device with proprietary engineering. BI has made device patent listings for these products, and the FTC has included BI inhaler patents in its challenge campaigns. BI announced out-of-pocket cost caps for its inhaler products following the November 2023 FTC campaign, but has not provided complete public disclosure of which specific device patents it has delisted versus maintained.
Amphastar: Baqsimi Glucagon Nasal Spray
Amphastar Pharmaceuticals received FTC warning letters in April 2024 regarding Baqsimi (glucagon) nasal spray listings. Baqsimi is the first intranasally administered glucagon for severe hypoglycemia and holds a unique market position. The nasal spray delivery system uses proprietary device technology, and Amphastar has listed device mechanism patents alongside the glucagon composition patents. The FTC’s challenge argues the device patents do not claim glucagon itself and should be removed. Amphastar’s response has not been publicly disclosed in full, and the product remains within the period of regulatory exclusivity for the indication, which provides some insulation from the near-term generic entry question regardless of Orange Book listing status.
What Happens to the 30-Month Stay When a Patent Is Delisted Mid-Litigation?
Mid-Litigation Delistings and Their Effect on FDA Approval Timelines
When an Orange Book patent is delisted while Hatch-Waxman litigation is pending, the 30-month stay associated with that patent does not automatically continue. Under FDA regulations, a delistment removes the patent from the Orange Book, and if the stay was based solely on that patent’s listing, the generic applicant can request FDA to proceed with final approval review. The brand manufacturer retains the right to pursue the patent infringement claim in court, but it no longer carries the administrative stay benefit.
The practical effect is that mid-litigation delistings can dramatically accelerate a generic’s path to market. In the Teva v. Amneal case, the entire 30-month stay that had been blocking Amneal’s ProAir HFA generic application rested on the five inhaler device patents that were ultimately ordered delisted. Once those patents were removed from the Orange Book, the stay’s basis was eliminated. Amneal’s ANDA could proceed through final FDA approval review without waiting for the 30-month period to expire or for a final judgment on the merits of the now-delisted patents.
Can a Brand Manufacturer Refile Device Patents Under Different Use Codes?
This is a question that some brand IP teams have explored as a workaround: if a device patent cannot be listed as a drug product patent, can it be relisted as a method-of-use patent with a use code tied to the approved therapeutic indication? The answer is generally no, for several reasons. First, a method-of-use patent must claim a method of using the drug for a specific indication. A patent claiming inhaler dose counter mechanism components does not claim a method of using albuterol sulfate for bronchospasm; it claims a device feature. Changing the listing category does not change what the patent claims. Second, FDA regulations require patent submissions to identify which claims of the patent qualify for each category of listing. If the claims are device-only, there is no compliant listing category available for them regardless of how the use code is structured. Third, attempting to relist a court-ordered delisted patent under an alternative category would expose the company to sanctions risk and further antitrust liability.
Supply Chain Implications: What Generic Entry at Scale Means for Manufacturing
Inhaler-Specific Manufacturing Challenges for Generic Entrants
Patent clearance is necessary but not sufficient for generic inhaler entry. Pressurized metered-dose inhalers and dry powder inhalers require specialized manufacturing, formulation expertise, and device compatibility testing that most generic manufacturers lack at the scale of major branded products. The FDA’s bioequivalence requirements for orally inhaled drug products are more complex than for oral tablets: they require in vitro aerodynamic particle size distribution testing, drug deposition studies, and pharmacokinetic studies in human subjects. The FDA’s guidance on ANDA requirements for complex inhalation products has evolved over the past decade and is substantially more demanding than the guidance for simple oral generics.
This means that even after Orange Book device patent delistings clear the regulatory path, the competitive timeline for respiratory generics may still be measured in years rather than months. Companies like Amneal, Cipla, Lupin, Sandoz (now Aurobindo following the Sandoz spin-off), and Sun Pharma have invested in pMDI and DPI manufacturing capabilities specifically to compete in this market segment. But the gap between ANDA filing and commercially competitive launch volume remains substantial for inhalers in a way that does not apply to simple oral generics.
Epinephrine Autoinjectors: Teva’s EpiPen-Adjacent Competitive Position
The FTC’s challenge to epinephrine autoinjector device patent listings targeted products including Teva’s generic epinephrine autoinjector and kaleo’s AUVI-Q. The branded EpiPen market (Viatris/Pfizer) has already faced significant competitive pressure from both authorized generics and ANDA-approved generics since the original price controversy in 2016. Device patent listings on autoinjector mechanism components, needle retraction systems, and audible dose indicators have been used by multiple manufacturers to maintain barriers in this market segment. Kaleo’s voluntary delistings for AUVI-Q removed some of those barriers, and Teva’s December 2025 broad delisting program included epinephrine autoinjector patents in the group of 200-plus removed listings.
Regulatory Pathway Strategy: Designing an IP Portfolio for the Post-Crackdown World
How Should Brand Manufacturers Restructure Their Patent Listing Strategy?
The optimal IP strategy for brand pharmaceutical manufacturers with combination drug-device products now requires separating the protection stack into two distinct layers: Orange Book-eligible patents (molecule, formulation, method of use) and non-Orange-Book-eligible patents (device, packaging, manufacturing, distribution). This is not a weakening of IP protection; it is a more accurate deployment of that protection.
Device patents remain valuable. A proprietary inhaler design, auto-injector mechanism, or drug delivery platform can be protected by patents that a generic manufacturer must engineer around when designing its own device. Those patents can still be asserted in regular patent infringement suits if a generic copies the device. What they cannot do under the current legal standard is generate 30-month Orange Book stays. Brand manufacturers who understand this distinction can build device IP programs that provide genuine commercial differentiation through technical barriers without creating antitrust liability through improper Orange Book listings.
Formulation Patents as the Primary Post-Device Defense
With device patents off the Orange Book table, formulation patents become more commercially critical. A formulation patent that claims the active ingredient in a specific particle size, carrier composition, surfactant system, or propellant combination will satisfy the Teva v. Amneal standard because the API appears in the claims. For dry powder inhalers where the formulation is key to efficacy, these patents provide legitimate Orange Book listing rights and 30-month stay triggers against generic filers who have not achieved bioequivalent formulation performance.
Method-of-use patents covering specific dosing regimens, patient populations, or combination therapy indications approved by FDA also remain fully listable. Brand manufacturers who have not optimized their method-of-use patent portfolio, either by filing method patents tied specifically to approved indications or by ensuring use codes are accurate and defensible, should audit this layer of protection as the device patent layer diminishes.
Pricing Pressure Scenarios: Modelling Generic Entry for Challenged Products
Generic Entry Scenarios for Teva’s ProAir HFA Post-Delisting
In the U.S. short-acting beta-agonist inhaler market, ProAir HFA held a dominant position for years as one of the primary branded albuterol products. Post-delistings, assuming Amneal receives final FDA approval within 12 months, the competitive dynamics follow the standard generic entry pricing model: first generic entry at approximately 80 percent of brand price, rapid additional entrants reducing price further, with the brand maintaining a rump volume at premium pricing for insured patients with formulary coverage. U.S. generic inhaler pricing is also compressed by the $35 out-of-pocket cap commitments from multiple major manufacturers, which limit the price differential a consumer experiences at the pharmacy counter.
For Teva’s brand revenues specifically, the shift from ProAir HFA branded sales to generic volume (in which Teva itself competes as a generics company) is partly a portfolio transition rather than a pure revenue loss. Teva has the manufacturing infrastructure to compete in the generic albuterol market and may have positioned itself to capture generic volume share even as branded ProAir revenues decline. The net financial impact depends on branded vs. generic margin profiles and the pace of formulary shifts away from branded ProAir.
GLP-1 Agonist Market: Ozempic Device Listing Challenge and Its Long-Term Effect
The FTC’s challenge to Novo Nordisk’s Ozempic device patent listings has no near-term commercial effect because the semaglutide molecule and its approved formulations remain protected by patents expiring in the early 2030s. But the precedent matters for Novo Nordisk’s long-range exclusivity planning. Every device improvement to the FlexPen and FlexTouch delivery systems that Novo Nordisk develops for semaglutide, dulaglutide-equivalent, and next-generation GLP-1 products now needs to be evaluated under the Teva v. Amneal standard before being submitted for Orange Book listing. Injector pen ergonomic improvements, dose confirmation systems, and connected health device integrations are all commercially valuable and patentable. None of them is Orange Book-listable unless the claims specifically incorporate the API.
What This Means for Patients and Payers
Out-of-Pocket Cost Impact: Inhalers as the Test Case
The FTC’s November 2023 campaign produced one immediate and measurable consumer benefit beyond patent delistings: AstraZeneca, Boehringer Ingelheim, and GlaxoSmithKline all announced $35 per-month out-of-pocket cost caps for their inhaler products in direct response to the FTC’s warning letters and associated public pressure. [4] That price action preceded any generic entry and represented a competitive response by brand manufacturers to the visibility of the FTC challenge. It is not a substitute for generic competition, which typically reduces net prices more substantially over time, but it is a documented price response to the enforcement campaign.
For payers, the longer-term benefit comes from formulary flexibility. When branded drugs with no meaningful remaining patent exclusivity (other than improperly listed device patents) compete against approved generics, payers can tier generics preferentially and shift formulary access. That formulary shift reduces net prices for the payer through generic discounts and rebate realignment on the branded tier. The IQVIA Institute has documented that generic drug savings to the U.S. healthcare system have exceeded $300 billion annually in recent years. The removal of barriers to generic entry for respiratory products specifically, which are among the most expensive long-term medication categories for insured populations, is a material contribution to that savings pool.
Patient Adherence and Access: The Health Consequence of Pricing Barriers
The FTC’s own filings cite the 2018 American Thoracic Society policy statement finding that high inhaler costs reduce patient adherence. [17] The clinical literature on asthma and COPD outcomes consistently shows that cost-related non-adherence, patients rationing or discontinuing controller medications due to out-of-pocket expense, increases emergency department visits, hospitalizations, and mortality. The commercial implications of Orange Book patent policy connect directly to these health outcomes. Improper listings that delay generic entry for essential respiratory medications are not just an antitrust violation; they have documented public health consequences that the FTC is now explicitly citing in its enforcement rationale.
Key Takeaways
The FTC challenged more than 600 Orange Book patent listings between September 2023 and May 2025, targeting device component patents for inhalers, epinephrine autoinjectors, GLP-1 injector pens, and glucagon nasal spray systems.
The Federal Circuit’s December 20, 2024 ruling in Teva v. Amneal (No. 24-1936) sets a binding appellate standard: Orange Book listings must claim at least the active pharmaceutical ingredient. Device-component-only patents do not qualify.
Teva’s $35 million October 2025 settlement of the QVAR antitrust class action is the first monetary resolution of a private antitrust case predicated on improper Orange Book listings. It gives plaintiffs’ attorneys a confirmed settlement template for similar cases.
Teva removed more than 200 patents from the Orange Book in December 2025 covering more than 30 branded products, the largest single-company voluntary delisting in the agency’s history.
The FTC’s Orange Book campaign has continued under the Trump administration, with Chairman Andrew Ferguson citing the President’s executive order on drug pricing as authority for the May 2025 round of warning letters.
NDA holders with combination drug-device portfolios must audit every listed device patent against the Teva v. Amneal standard. Any patent that does not claim the API in its claims is now legally indefensible as an Orange Book listing and should be voluntarily removed.
The commercial protection for device innovations remains intact through regular patent enforcement. What has changed is the ability to use device patents as Orange Book-mediated 30-month stays.
Formulation patents, method-of-use patents, and drug substance patents remain fully listable and continue to provide legitimate exclusivity protection and 30-month stay rights.
Private antitrust class actions following the QVAR model are the most significant enforcement risk for manufacturers who maintain challenged listings after the Federal Circuit ruling. Antitrust counsel review of listing decisions is now essential, not optional.
DrugPatentWatch’s Orange Book patent tracking, combined with FTC challenge letter databases, provides the most efficient starting point for a portfolio-wide compliance audit.
FAQ: Orange Book Delisting, FTC Enforcement, and Pipeline Intelligence
1. Can a brand manufacturer re-list a patent after voluntarily delisting it in response to an FTC warning letter?
Generally no. Under FDA regulations at 21 C.F.R. § 314.53, once a patent is withdrawn from the Orange Book by the NDA holder, relisting requires a new submission demonstrating compliance with listing requirements. For patents that have been delisted under FTC pressure or court order, relisting the same patent would immediately revive both the FTC enforcement action and the antitrust exposure established by private litigation. There is no known case of successful relisting after a court-ordered delisting.
2. What is the difference between a patent delisting and a patent expiration for Orange Book purposes?
Expiration means the patent’s 20-year term has run and the patent enters the public domain. Delisting means the patent is removed from the Orange Book regardless of whether it is still in force. A delisted-but-active patent can still be enforced through regular district court infringement suits; it simply no longer generates 30-month stay rights when a generic files a Paragraph IV certification. An expired patent cannot be enforced at all. Delisting does not extinguish the patent.
3. How does the FTC Orange Book challenge interact with FDA’s formal patent dispute process under 21 C.F.R. § 314.53(f)(1)?
The FTC uses the FDA’s existing 21 C.F.R. § 314.53(f)(1) dispute mechanism to formally notify the FDA of its challenge. The FDA transmits the dispute to the NDA holder, who has 30 days to withdraw the listing or certify under penalty of perjury that it is proper. If the manufacturer certifies, the FDA takes no administrative action and the listing remains. The FTC must then pursue enforcement through litigation or other means. The administrative dispute process does not give the FDA authority to order delistings independently of manufacturer consent or court order.
4. Does the Teva v. Amneal ruling affect method-of-use patents currently listed in the Orange Book?
No. The Federal Circuit’s decision specifically addressed drug product patents that covered device components without claiming the active ingredient. Method-of-use patents that claim an approved therapeutic indication remain listable under 21 U.S.C. § 355(b)(1)(A)(viii)(III). Method patents do face their own set of challenges, including carve-out strategies through Section viii statements and skinny labeling, but the Teva v. Amneal ruling did not affect their listing eligibility. Only device-component patents that fail to claim the API are directly covered by the ruling.
5. What is the ‘patent thicket’ strategy and how does the delisting wave affect it?
A patent thicket is the accumulation of multiple secondary patents around a branded drug product that collectively extend market exclusivity beyond the primary compound patent. The Orange Book delisting wave removes one layer of the thicket, specifically device mechanism and delivery system patents that do not claim the API. Formulation patents, polymorph patents, extended-release composition patents, and method-of-use patents that do claim the API remain intact as listable barriers. The thicket is thinner but not dissolved.
6. Can a generic manufacturer counterclaim for delisting without waiting for FTC action?
Yes. Amneal’s successful delisting counterclaim in Teva v. Amneal demonstrates that a generic defendant in Hatch-Waxman infringement litigation can bring its own counterclaim seeking Orange Book delisting of allegedly improper patents. The antitrust counterclaims Amneal filed, alleging monopolization and attempted monopolization based on the improper listings, survived Teva’s motion to dismiss and are proceeding separately. Generic manufacturers should treat the delisting counterclaim as a standard tool in their Hatch-Waxman defense kit for any case involving device component patents.
7. How should investors model Orange Book listing risk in pharma pipeline valuations?
Investors should separate the patent exclusivity stack for any combination drug-device asset into Orange-Book-eligible (API-claiming formulation, composition, and method patents) and non-Orange-Book-eligible (device component patents) layers. The effective exclusivity period for competitive modeling purposes ends at the last eligible patent’s expiration, not the last listed patent. For challenged listings that remain in place, a probability-weighted litigation cost and settlement exposure should be included as a liability, using the QVAR settlement’s 11-percent-of-damages reference point as a floor for negotiations.
8. What role does DrugPatentWatch play in monitoring Orange Book listing challenges?
DrugPatentWatch tracks Orange Book patent listings, expiration dates, ANDA filings, Paragraph IV certifications, and FTC challenge activity across the entire approved drug product universe. For portfolio managers, compliance teams, and competitive intelligence analysts, its database provides real-time visibility into which products have been challenged, which patents have been voluntarily delisted or court-ordered delisted, and which ANDA filings may be close to final approval as stay-generating device patents are removed. The tool is particularly valuable for mapping the competitive timeline gap between patent challenges and actual generic market entry.
9. What is the relationship between Orange Book listing challenges and pay-for-delay antitrust liability?
Improper Orange Book listings increase the probability that subsequent Hatch-Waxman settlements will be scrutinized under the FTC v. Actavis framework for reverse payment antitrust violations. When a brand manufacturer sues a generic on a patent that does not meet listing requirements, the litigation is a stronger candidate for sham litigation characterization. A settlement where the brand pays the generic to exit, or grants it a licensing arrangement valued above avoided litigation cost, on a sham litigation basis carries compounded antitrust exposure from both the settlement structure and the underlying listing impropriety.
10. Will the FTC bring a standalone Section 5 enforcement action against a pharma company for Orange Book listings?
As of mid-2026, the FTC has not brought a standalone Section 5 enforcement action specifically for Orange Book listing violations. The agency has relied on warning letters, FDA dispute filings, civil investigative demands, and amicus briefs in private litigation. The most likely trigger for a standalone enforcement action would be a manufacturer that maintains improper listings after a court order or Federal Circuit ruling covers those specific patents. Given that Teva’s December 2025 broad delisting effectively resolved the most egregious pending cases, the FTC may continue to use its current indirect enforcement model, allowing private antitrust class actions to do much of the damages work while the agency focuses on structural remedies.
References
DrugPatentWatch. (2025, April 17). Pharmaceutical patent use codes: The definitive technical and strategic guide to Orange Book method-of-use patents, skinny labeling, and induced infringement risk. https://www.drugpatentwatch.com/blog/patent-use-codes-for-pharmaceutical-products-a-comprehensive-analysis/
Federal Trade Commission. (2023, September 14). FTC issues policy statement on brand pharmaceutical manufacturers’ improper listing of patents in the Food and Drug Administration’s ‘Orange Book.’ https://www.ftc.gov/news-events/news/press-releases/2023/09/ftc-issues-policy-statement-brand-pharmaceutical-manufacturers-improper-listing-patents-food-drug
Mayer Brown. (2024, May). US FTC continues aggressive scrutiny of pharmaceutical patents listed in the Orange Book. https://www.mayerbrown.com/en/insights/publications/2024/05/us-ftc-continues-aggressive-scrutiny-of-pharmaceutical-patents-listed-in-the-orange-book
Federal Trade Commission. (2024, April 30). FTC expands patent listing challenges, targeting more than 300 junk listings for diabetes, weight loss, asthma and COPD drugs. https://www.ftc.gov/news-events/news/press-releases/2024/04/ftc-expands-patent-listing-challenges-targeting-more-300-junk-listings-diabetes-weight-loss-asthma
White & Case LLP. (2024, August). The current status of FTC’s Orange Book listings challenge: A mixed bag. https://www.whitecase.com/insight-our-thinking/current-status-ftcs-orange-book-listings-challenge-mixed-bag
Federal Trade Commission. (2025, May). FTC renews challenge of more than 200 improper patent listings. https://www.ftc.gov/news-events/news/press-releases/2025/05/ftc-renews-challenge-more-200-improper-patent-listings
Cooley LLP. (2025, January 2). Teva v. Amneal ruling interprets Orange Book listing statute, affirms delisting of device patents. https://www.cooley.com/news/insight/2025/2025-01-02-teva-v-amneal-ruling-interprets-orange-book-listing-statute-affirms-delisting-of-device-patents
A&O Shearman. (2024, June 18). New Jersey District Court orders delisting of Teva inhaler patents from the Orange Book. https://www.lit-ip.aoshearman.com/new-jersey-district-court-orders-delisting
Patently-O. (2024, December 20). Orange Book device patent listings: Understanding Teva v. Amneal. https://patentlyo.com/patent/2024/12/orange-listings-understanding.html
Fish & Richardson. (2025, March 3). Recent decisions and FTC challenges dictate caution when listing patents in the Orange Book. https://www.fr.com/insights/thought-leadership/blogs/recent-decisions-and-ftc-challenges-dictate-caution-when-listing-patents-in-the-orange-book/
PharmaTutor. (2025, October 29). Teva reaches USD 35 million settlement in QVAR antitrust case. https://www.pharmatutor.org/pharma-news/2025/teva-reaches-usd-35-million-settlement-in-qvar-antitrust-case
Haug Partners LLP. (2025, November 24). Listing a liability: The Orange Book’s new antitrust frontier. https://haugpartners.com/article/listing-a-liability-the-orange-books-new-antitrust-frontier/
Georgetown O’Neill Institute. (2025, November 6). Recent developments in Orange Book litigation: How patent disputes shape prescription drug affordability. https://oneill.law.georgetown.edu/recent-developments-in-orange-book-litigation-how-patent-disputes-shape-prescription-drug-affordability/
Federal Trade Commission. (2024, March). FTC files amicus brief in asthma inhaler patent dispute. https://www.ftc.gov/news-events/news/press-releases/2024/03/ftc-files-amicus-brief-asthma-inhaler-patent-dispute
FTC v. AbbVie Inc., 976 F.3d 327 (3d Cir. 2020).
Federal Trade Commission. (2025, December 10). Teva removes over 200 improper patent listings under pressure from FTC. https://www.ftc.gov/news-events/news/press-releases/2025/12/teva-removes-over-200-improper-patent-listings-under-pressure-ftc
Federal Trade Commission. (2024, March 22). Brief for Fed. Trade Comm’n as Amicus Curiae, Teva Branded Pharmaceutical Products R&D v. Amneal Pharmaceuticals of New York [PDF]. https://www.ftc.gov/system/files/ftc_gov/pdf/ftc_brief_as_amicus_curiae_teva_amneal.pdf
Teva Branded Pharm. Prods. R&D, Inc. v. Amneal Pharms. of N.Y., LLC, No. 24-1936, 124 F.4th 898 (Fed. Cir. Dec. 20, 2024).
CWSL Intellectual Property Review. (2026, January). Listed, stayed, delayed: Brand-name drug manufacturer’s strategic patent listings and the breakdown of the Hatch-Waxman Act. https://www.cwsl-intellectual-property.com/post/listed-stayed-delayed
DrugPatentWatch. (2026, March 1). Master FDA Orange Book codes to predict generic drug launch dates. https://www.drugpatentwatch.com/blog/master-fda-orange-book-codes-to-predict-generic-drug-launch-dates/
